

Karin M Danzer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7244821/publications.pdf>

Version: 2024-02-01

63
papers

6,187
citations

136885

32
h-index

123376

61
g-index

64
all docs

64
docs citations

64
times ranked

8631
citing authors

#	ARTICLE	IF	CITATIONS
1	Different Species of α -Synuclein Oligomers Induce Calcium Influx and Seeding. <i>Journal of Neuroscience</i> , 2007, 27, 9220-9232.	1.7	708
2	Exosomal cell-to-cell transmission of alpha synuclein oligomers. <i>Molecular Neurodegeneration</i> , 2012, 7, 42.	4.4	708
3	Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. <i>Nature Neuroscience</i> , 2015, 18, 631-636.	7.1	652
4	Induction of α -synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies. <i>Brain</i> , 2016, 139, 481-494.	3.7	349
5	Heat shock protein 70 modulates toxic extracellular α -synuclein oligomers and rescues trans-synaptic toxicity. <i>FASEB Journal</i> , 2011, 25, 326-336.	0.2	276
6	TDP-43 is intercellularly transmitted across axon terminals. <i>Journal of Cell Biology</i> , 2015, 211, 897-911.	2.3	263
7	Seeding induced by α -synuclein oligomers provides evidence for spreading of α -synuclein pathology. <i>Journal of Neurochemistry</i> , 2009, 111, 192-203.	2.1	254
8	Inflammatory dysregulation of blood monocytes in Parkinson's disease patients. <i>Acta Neuropathologica</i> , 2014, 128, 651-663.	3.9	216
9	Single Particle Characterization of Iron-induced Pore-forming α -Synuclein Oligomers. <i>Journal of Biological Chemistry</i> , 2008, 283, 10992-11003.	1.6	204
10	Systematic Comparison of the Effects of Alpha-synuclein Mutations on Its Oligomerization and Aggregation. <i>PLoS Genetics</i> , 2014, 10, e1004741.	1.5	168
11	Hot-spot KIF5A mutations cause familial ALS. <i>Brain</i> , 2018, 141, 688-697.	3.7	167
12	Brain-Permeable Small-Molecule Inhibitors of Hsp90 Prevent α -Synuclein Oligomer Formation and Rescue α -Synuclein-Induced Toxicity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 332, 849-857.	1.3	162
13	Age-dependent defects of alpha-synuclein oligomer uptake in microglia and monocytes. <i>Acta Neuropathologica</i> , 2016, 131, 379-391.	3.9	140
14	Extracellular vesicle sorting of α -Synuclein is regulated by sumoylation. <i>Acta Neuropathologica</i> , 2015, 129, 695-713.	3.9	136
15	Proteomic and functional alterations in brain mitochondria from Tg2576 mice occur before amyloid plaque deposition. <i>Proteomics</i> , 2007, 7, 605-616.	1.3	122
16	Peripheral monocytes are functionally altered and invade the CNS in ALS patients. <i>Acta Neuropathologica</i> , 2016, 132, 391-411.	3.9	116
17	Mutual exacerbation of peroxisome proliferator-activated receptor β coactivator 1 α deregulation and α -synuclein oligomerization. <i>Annals of Neurology</i> , 2015, 77, 15-32.	2.8	112
18	<i>NEK1</i> mutations in familial amyotrophic lateral sclerosis. <i>Brain</i> , 2016, 139, e28-e28.	3.7	105

#	ARTICLE	IF	CITATIONS
19	Two novel mutations in conserved codons indicate that CHCHD10 is a gene associated with motor neuron disease. <i>Brain</i> , 2014, 137, e309-e309.	3.7	101
20	Increased Immune Activation by Pathologic α -Synuclein in Parkinson's Disease. <i>Annals of Neurology</i> , 2019, 86, 593-606.	2.8	95
21	Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. <i>Brain</i> , 2014, 137, 2938-2950.	3.7	91
22	PGC-1 α is a male-specific disease modifier of human and experimental amyotrophic lateral sclerosis. <i>Human Molecular Genetics</i> , 2013, 22, 3477-3484.	1.4	74
23	Serum microRNAs in sporadic amyotrophic lateral sclerosis. <i>Neurobiology of Aging</i> , 2015, 36, 2660.e15-2660.e20.	1.5	64
24	AMPA-receptor-mediated excitatory synaptic transmission is enhanced by iron-induced α -synuclein oligomers. <i>Journal of Neurochemistry</i> , 2011, 117, 868-878.	2.1	60
25	Release and uptake of pathologic alpha-synuclein. <i>Cell and Tissue Research</i> , 2018, 373, 175-182.	1.5	57
26	Heterozygous <i>Tbk1</i> loss has opposing effects in early and late stages of ALS in mice. <i>Journal of Experimental Medicine</i> , 2019, 216, 267-278.	4.2	57
27	Proteasome impairment by α -synuclein. <i>PLoS ONE</i> , 2017, 12, e0184040.	1.1	49
28	Autoproteolytic Fragments Are Intermediates in the Oligomerization/Aggregation of the Parkinson's Disease Protein Alpha-Synuclein as Revealed by Ion Mobility Mass Spectrometry. <i>ChemBioChem</i> , 2011, 12, 2740-2744.	1.3	44
29	α -Synuclein in Parkinson's Disease: Pathogenic Function and Translation into Animal Models. <i>Neurodegenerative Diseases</i> , 2014, 14, 1-17.	0.8	39
30	Impaired activation of ALS monocytes by exosomes. <i>Immunology and Cell Biology</i> , 2017, 95, 207-214.	1.0	39
31	Chronic Treatment with Novel Small Molecule Hsp90 Inhibitors Rescues Striatal Dopamine Levels but Not α -Synuclein-Induced Neuronal Cell Loss. <i>PLoS ONE</i> , 2014, 9, e86048.	1.1	35
32	ALS-causing mutations differentially affect PGC-1 α expression and function in the brain vs. peripheral tissues. <i>Neurobiology of Disease</i> , 2017, 97, 36-45.	2.1	35
33	Dysregulation of a novel miR-1825/TBCB/TUBA4A pathway in sporadic and familial ALS. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 4301-4319.	2.4	34
34	Telomere shortening leads to earlier age of onset in ALS mice. <i>Aging</i> , 2016, 8, 382-393.	1.4	31
35	CHCHD10 mutations p.R15L and p.G66V cause motoneuron disease by haploinsufficiency. <i>Human Molecular Genetics</i> , 2018, 27, 706-715.	1.4	30
36	α -synuclein interacts with SOD1 and promotes its oligomerization. <i>Molecular Neurodegeneration</i> , 2015, 10, 66.	4.4	29

#	ARTICLE	IF	CITATIONS
37	LRRK2 contributes to monocyte dysregulation in Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2016, 4, 123.	2.4	29
38	The Role of Lipids in the Initiation of α -Synuclein Misfolding. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 562241.	1.8	29
39	In Vivo Protein Complementation Demonstrates Presynaptic α -Synuclein Oligomerization and Age-Dependent Accumulation of 8-mer Oligomer Species. <i>Cell Reports</i> , 2019, 29, 2862-2874.e9.	2.9	26
40	SQSTM1/p62 variants in 486 patients with familial ALS from Germany and Sweden. <i>Neurobiology of Aging</i> , 2020, 87, 139.e9-139.e15.	1.5	23
41	T-cell dysregulation is associated with disease severity in Parkinson's Disease. <i>Journal of Neuroinflammation</i> , 2021, 18, 250.	3.1	22
42	Quantifying amyloid fibrils in protein mixtures via infrared attenuated-total-reflection spectroscopy. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 4015-4021.	1.9	20
43	Screening for CHCHD10 mutations in a large cohort of sporadic ALS patients: no evidence for pathogenicity of the p.P34S variant: Table 1. <i>Brain</i> , 2016, 139, e8-e8.	3.7	20
44	Functional protein kinase arrays reveal inhibition of p21-activated kinase 4 by α -synuclein oligomers. <i>Journal of Neurochemistry</i> , 2007, 103, 2401-2407.	2.1	18
45	The Golgi-Localized β -Ear-Containing ARF-Binding (GGA) Proteins Alter Amyloid- β Precursor Protein (APP) Processing through Interaction of Their GAE Domain with the Beta-Site APP Cleaving Enzyme 1 (BACE1). <i>PLoS ONE</i> , 2015, 10, e0129047.	1.1	17
46	Aggregated α -Synuclein Increases SOD1 Oligomerization in a Mouse Model of Amyotrophic Lateral Sclerosis. <i>American Journal of Pathology</i> , 2016, 186, 2152-2161.	1.9	17
47	Hemizygous deletion of <i>Tbk1</i> worsens neuromuscular junction pathology in TDP-43 transgenic mice. <i>Experimental Neurology</i> , 2021, 335, 113496.	2.0	15
48	Longitudinal diffusion tensor magnetic resonance imaging analysis at the cohort level reveals disturbed cortical and callosal microstructure with spared corticospinal tract in the TDP-43G298S ALS mouse model. <i>Translational Neurodegeneration</i> , 2019, 8, 27.	3.6	13
49	Intracellular Alpha-Synuclein and Immune Cell Function. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 562692.	1.8	13
50	Gelsolin co-occurs with Lewy bodies in vivo and accelerates α -synuclein aggregation in vitro. <i>Biochemical and Biophysical Research Communications</i> , 2011, 412, 32-38.	1.0	12
51	Protein Binding Partners of Dysregulated miRNAs in Parkinson's Disease Serum. <i>Cells</i> , 2021, 10, 791.	1.8	11
52	Age Increases Monocyte Adhesion on Collagen. <i>Scientific Reports</i> , 2017, 7, 46532.	1.6	10
53	Rapid, convenient and efficient kit-independent detection of SARS-CoV-2 RNA. <i>Journal of Virological Methods</i> , 2020, 286, 113965.	1.0	10
54	Haploinsufficiency of TANK-binding kinase 1 prepones age-associated neuroinflammatory changes without causing motor neuron degeneration in aged mice. <i>Brain Communications</i> , 2020, 2, fcaa133.	1.5	9

#	ARTICLE	IF	CITATIONS
55	Drug Targets from Genetics: Alpha-Synuclein. <i>CNS and Neurological Disorders - Drug Targets</i> , 2011, 10, 712-723.	0.8	9
56	Commentary: alpha-synuclein interacts with SOD1 and promotes its oligomerization. <i>Journal of Neurology and Neuromedicine</i> , 2016, 1, 28-30.	0.9	9
57	Enhanced Hyaluronan Signaling and Autophagy Dysfunction by VPS35 D620N. <i>Neuroscience</i> , 2020, 441, 33-45.	1.1	8
58	A serum microRNA sequence reveals fragile X protein pathology in amyotrophic lateral sclerosis. <i>Brain</i> , 2021, 144, 1214-1229.	3.7	8
59	Methylome analysis of ALS patients and presymptomatic mutation carriers in blood cells. <i>Neurobiology of Aging</i> , 2022, 116, 16-24.	1.5	8
60	The Golgi-localized, gamma ear-containing, ARF-binding (GGA) protein family alters alpha synuclein (1±-syn) oligomerization and secretion. <i>Aging</i> , 2017, 9, 1677-1697.	1.4	7
61	Reply: Adult-onset distal spinal muscular atrophy: a new phenotype associated with KIF5A mutations. <i>Brain</i> , 2019, 142, e67-e67.	3.7	1
62	Increased NF-L levels in the TDP-43G298S ALS mouse model resemble NF-L levels in ALS patients. <i>Acta Neuropathologica</i> , 2022, 144, 161-164.	3.9	1
63	Inside Cover: Autoproteolytic Fragments Are Intermediates in the Oligomerization/Aggregation of the Parkinson's Disease Protein Alpha-Synuclein as Revealed by Ion Mobility Mass Spectrometry (<i>ChemBioChem</i> 18/2011). <i>ChemBioChem</i> , 2011, 12, 2706-2706.	1.3	0